Mode
Text Size
Log in / Sign up
N/A Completed N=329

A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population

Source: ClinicalTrials.gov NCT00930722 ↗
Enrolled (actual)
329
Serious AEs
0.0%
Results posted
May 2011
Primary outcomePrimary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 0 Participants

Summary

This is a prospective, non-interventional, non comparative drug study. The efficacy of Quinapril in Asian population has been evaluated, but specifically in Indian patients the data is sparse. Data in a real world setting in a large population of Indian patients would shed more light on the safety, tolerability and effectiveness of Quinapril in the Indian population.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
1; 0 —
SECONDARY
Change From Baseline in Systolic Blood Pressure (SBP) at Week 12
142.16; -9.40 —
SECONDARY
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12
86.31; -3.93 —
SECONDARY
Change From Baseline in SBP at Week 52
— —
SECONDARY
Change From Baseline in DBP at Week 52
— —
SECONDARY
Change From Pre-treatment in SBP at Week 0
154.06; -12.49 —
SECONDARY
Change From Pre-treatment in DBP at Week 0
92.82; -6.74 —
SECONDARY
Number of Participants Achieving BP Goal at Week 12
78 —
SECONDARY
Number of Participants With Achievement of BP Goal at Week 52
— —
SECONDARY
Duration of Monotherapy With Quinapril
— —
SECONDARY
Mean Daily Dose of Study Medication
11.28 —
SECONDARY
Number of Participants With Preference for add-on Anti-hypertensive Therapy
321; 1; 1 —

Eligibility Criteria

Inclusion Criteria

  • Patients already on therapy with Acupil® for a minimum period of 4 weeks, Evidence of a personally signed and dated informed consent document

Exclusion Criteria

  • Patients having a Week 0 visit blood pressure reading of more than 180/110 mm of Hg will not be eligible to participate in the study.
  • Women of child bearing age, not willing to use contraceptives, will not be eligible for the study
  • Women using oral contraceptives will also not be included in the study
  • Patients who have received any drug other than Acupil® as the first prescribed antihypertensive would not be eligible for enrollment into the trial
  • Patients having any complication at Week 0 visit which would require more thorough investigations or who required more than one anti-hypertensive drug at the time of initiation of their therapy will not be included in the study
  • Patients having any contraindications as per the LPD of Acupil®
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00930722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search